Skyrizi Subcutaneous Injection 150mg Pen 1mL, manufactured by AbbVie, contains Risankizumab (genetical recombination) (YJ code: 3999450G3020, 150mg 1mL kit). This IL-23 inhibitor is used for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis in adults.
Skyrizi Subcutaneous Injection 150mg Pen 1mL
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →